In addition, while anti-PD-1 therapy is typically used for advanced metastatic MSI CRC, the treatment-naïve status of all cases in this study revealed evidence of immune activation is notable in MSI MOD1, highlighting a differential response compared to the non-responder MSI MOD7 despite sharing the same MMR status. Here, MRC1 is linked to colorectal carcinoma.